Intended for healthcare professionals
Search
Toggle navigation
Current issue
Archive
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
Editorial board
For authors
Advertising
Contact us
News
Web Exclusives
Register
FREE
Sign in
×
Remember me
Not registered?
Forgot your password?
Antibiotic resistance and the use of combination treatments for acne
Tony Chu
Acne vulgaris is one of the most common skin conditions to affect mankind. It affects over 90% of adolescents, and in up to 30% of patients acne persists into adult life. At the age of 40, the incidence is 5% in women and 1% in men. The standard treatment for acne involves the use of topical retinoids or other comedolytic agents to address the primary lesion of acne, the microcomedone, while antibacterial agents or antibiotics are used to control Propionibacterium acnes and thus to control the inflammatory lesions of acne.
Dermatology in practice
2002;
10
(4): 19–20
To continue reading this article, please
sign in
or
register
.
Follow us on
|
|
Latest News
Arcutis receives FDA approval for steroid-free plaque psoriasis treatment
Positive results for Biogen’s lupus drug published in NEJM
Bristol Myers Squibb’s Opdualag approved by CHMP for melanoma
NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis
Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
This site uses cookies in order to function properly and to allow us to improve our service. By using this site you consent to the use of cookies as set out in our
privacy policy